Citius Oncology Achieves First Revenue Milestone with LYMPHIR™ Launch

Citius Oncology, Inc. has marked a significant milestone in its journey as a commercial oncology company by announcing its first reported revenue following the successful launch of LYMPHIR™, an innovative treatment for adult patients facing relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL). This new FDA-approved immunotherapy is a crucial development aimed to serve an underserved market in oncology.

On February 13, 2026, Leonard Mazur, Chairman and CEO of Citius Oncology, expressed his enthusiasm regarding the firm's financial results for the fiscal first quarter ending December 31, 2025. The company reported impressive revenue of $3.9 million driven by initial sales of LYMPHIR, marking a notable transition from a development-stage organization to a more robust commercial entity. This revenue is particularly essential as it showcases the company’s successful navigation through early commercialization, which required extensive preparation and coordination in clinical trials, manufacturing, distribution, and commercial infrastructure.

The launch of LYMPHIR in December 2025 was heralded as a pivotal inflection point for Citius Oncology. Mazur highlighted the company’s commitment to ensuring that physicians across the nation adopt LYMPHIR as a treatment option, striving to improve access for CTCL patients. His statement emphasized that since the start of 2026, oncology specialists have begun initiating treatment for patients with LYMPHIR, underlining their dedication to rapid adoption within the medical community.

With respect to distribution, Citius Oncology has set up a comprehensive national specialty distribution framework, ensuring that LYMPHIR is readily available in cancer treatment centers across the United States. This strategic approach not only facilitates product availability but also helps to foster rapid physician engagement through advanced, AI-enabled platforms aimed at optimizing field execution and penetration within a concentrated prescriber base.

Moreover, Citius is not only focusing on the domestic market; the company has developed an international access strategy through regional distribution partners and Named Patient Programs (NPPs) intended for markets in Europe and the Middle East. This approach enhances the potential for patient accessibility to LYMPHIR across diverse regions while complying with local regulations. This forward-looking strategy is vital for positioning the company in a competitive landscape of oncology therapies.

As for financial highlights, Citius Oncology reported a cash balance of $7.3 million as of December 31, 2025. They successfully completed a registered offering in the same month, raising approximately $15.1 million, a significant boost to their operational liquidity. The company’s R&D expenses for the quarter decreased to $1.0 million compared to $1.3 million in the previous year, reflecting a strategic focus on capital management as they advance their commercialization efforts. General and administrative expenses also saw a slight reduction, indicating ongoing efficiency improvements.

While Citius Oncology did report a net loss of approximately $5.5 million for the quarter, this was an improvement from the loss of $6.7 million during the same period the previous year. Such figures suggest that the company is on a trajectory toward a more sustainable business model as it continues to develop and market LYMPHIR, alongside other promising pipeline products.

Management’s commitment to capital management and the exploration of strategic opportunities appears well-aligned with their goal of enhancing shareholder value over the long term. With the launch of LYMPHIR, Citius Oncology not only bolsters its position in the oncology sector but also aims to transform the treatment landscape for patients affected by CTCL.

In summary, Citius Oncology’s initial revenue from LYMPHIR, coupled with their strategic initiatives and ongoing operational improvements, are clear indicators of potential growth in the competitive oncology market. Stakeholders can anticipate an ongoing evolution of the company’s market presence and contributions to patient care in the field of oncology.